Olverembatinib also exhibits antileukemic activity in imatinib-resistant/sensitive (GIST) cell lines and a GIST mouse model by inhibiting the phosphorylation of KIT and its downstream proteins, including AKT, ERK1/2, and STAT3 (36). Here, AKT1 is linked to gastrointestinal stromal tumor.